TrialEmerging microbes & infections2021

Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.

Xianmin Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.